We agree with the comments made by Devgan, et al. regarding use of National protocol for management of snake bite(1). We have some points to offer. Firstly, there is lack of literature regarding management of neonatal snake bite. The dose of ASV to be administered in such cases is open to further research. Secondly, we were guided a good clinical response to ASV beyond 25 vials. Though supportive therapy in the form of ventilatory support and management of shock formed the mainstay of therapy, it is difficult to postulate that response was attributable to these alone and not ASV.